Best Public Sector Innovation

The UK government invests heavily in the Life Sciences industry. It set out a bold new Life Sciences Vision in 2021 and has committed to investing £200m to allocate to innovative Life Sciences companies and has also committed £260m to support new treatments, clinical research and manufacturing. By 2027, the UK has committed to spending 2.4% of GDP on research and development.

The NHS is the largest single payer healthcare provider in the world, serving the needs of more than 50 million patients. The scale and challenges faced by the NHS leads to a large number of innovations and opportunities. Therefore, many of the innovations within the Life Sciences industry in the United Kingdom are driven by the needs of the NHS.

To recognise the innovations that are funded and driven by the UK government via the NHS and not-for-profit organisations has led the UK Prix Galien committee to announce a new award category for ‘Best Public Sector Innovation’. 


The «Best Public Sector Innovation» category recognizes outstanding
innovations in healthcare developed within or significantly supported by the public sector. This category aims to spotlight contributions that have profoundly impacted human health, aligning with the Prix Galien’s mission to celebrate excellence and innovation in medical advancements.
By introducing this category, the Prix Galien UK Committee aims to underscore the critical role of the public sector in advancing healthcare innovation.
It seeks to encourage public institutions, and private life sciences companies to collaborate with the public sector, to pursue groundbreaking work that can lead to significant health benefits globally. However, the innovation must have been majority funded and/or developed by the public sector.
1. Originality: The innovation should represent a novel approach or solution in healthcare, showcasing creativity and ingenuity.
2. Clinical Utility: The application of innovation in clinical settings or public health must provide clear benefits, improving patient care or health outcomes.
3. Knowledge Contribution: The entry should contribute valuable insights or findings that could influence future biomedical research or healthcare practices.
4. Impact: The overall effect on improving human health, including
accessibility, efficacy, and improvement in quality of life, will be assessed.
5. Independence from Market Factors: Consideration of the innovation’s merit will be made without regard to market size, development cost, or distribution challenges.


Play Video about DR. Mark Walport

Because innovation is transformative and transcends borders.

Other categories: